These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 32281456

  • 1. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ, Chen CC, Medeiros BC, McGuiness CB, Wilson SD, Walsh EH, Wade RL.
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [Abstract] [Full Text] [Related]

  • 2. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ, Chen CC, Medeiros BC, McGuiness CB, Wilson S, Horvath Walsh LE, Wade RL.
    Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
    [Abstract] [Full Text] [Related]

  • 3. Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.
    Pandya BJ, Chen CC, McGuiness CB, Sullivan L, Feng Q, Walsh E, Borate U.
    Expert Rev Hematol; 2022 Sep; 15(9):857-866. PubMed ID: 35924860
    [Abstract] [Full Text] [Related]

  • 4. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims.
    Sacks NC, Healey BE, Cyr PL, Slocomb T, James E, Beggs AH, Graham RJ.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1019-1026. PubMed ID: 33843254
    [Abstract] [Full Text] [Related]

  • 5. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL, Mathur K, Averitt AJ, Andrae DA.
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [Abstract] [Full Text] [Related]

  • 6. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
    Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B.
    J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
    [Abstract] [Full Text] [Related]

  • 7. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C.
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [Abstract] [Full Text] [Related]

  • 8. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
    Choong CK, Ford JH, Nyhuis AW, Robinson RL, Aurora SK.
    J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
    [Abstract] [Full Text] [Related]

  • 9. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
    Nazareth TA, Kariburyo F, Kirkemo A, Xie L, Pavlova-Wolf A, Bartels-Peculis L, Vaidya N, Sim JJ.
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
    [Abstract] [Full Text] [Related]

  • 10. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [Abstract] [Full Text] [Related]

  • 11. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [Abstract] [Full Text] [Related]

  • 12. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study.
    Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J.
    Adv Ther; 2024 Nov; 41(11):4049-4064. PubMed ID: 39240504
    [Abstract] [Full Text] [Related]

  • 13. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia.
    Pandya BJ, Qi CZ, Garnham A, Yang H, Shah MV, Zeidan AM.
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
    [Abstract] [Full Text] [Related]

  • 15. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H, Hao Y, Qi CZ, Chai X, Wu EQ.
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [Abstract] [Full Text] [Related]

  • 16. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE, Kaila S, Bayer V, Shaikh A, Shinde MU, Willey VJ, Napier MB, Singer JR.
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [Abstract] [Full Text] [Related]

  • 17. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M, Sharma A, Chung KC, Delea TE.
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [Abstract] [Full Text] [Related]

  • 18. Cost of epilepsy-related health care encounters in the United States.
    Borghs S, Beaty S, Parekh W, Kalilani L, Boudiaf N, Loewendorf A.
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1576-1581. PubMed ID: 33103619
    [Abstract] [Full Text] [Related]

  • 19. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, Stephenson JJ, Carson RT.
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
    Xing S, Batt K, Kuharic M, Bullano M, Caicedo J, Chakladar S, Markan R, Farahbakhshian S.
    J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.